BVS Bioventus Inc
Price (delayed)
$9.51
Market cap
$779.28M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.52
Enterprise value
$1.07B
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations
Highlights
The company's net income has surged by 79% YoY and by 15% QoQ
Bioventus's EPS has soared by 79% YoY and by 13% from the previous quarter
The quick ratio has declined by 12% year-on-year but it rose by 2.6% since the previous quarter
Bioventus's equity has decreased by 15% YoY
Key stats
What are the main financial stats of BVS
Market
Valuations
Earnings
Shares outstanding
81.94M
Market cap
$779.28M
Enterprise value
$1.07B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.22
Price to sales (P/S)
1.07
EV/EBIT
N/A
EV/EBITDA
21.68
EV/Sales
1.87
Revenue
$573.28M
Gross profit
$388.23M
Operating income
-$47.7M
Net income
-$33.54M
EBIT
-$43,000
EBITDA
$49.51M
Free cash flow
$37.79M
Per share
Balance sheet
Liquidity
EPS
-$0.52
EPS diluted
-$0.52
Free cash flow per share
$0.59
Book value per share
$1.82
Revenue per share
$8.88
TBVPS
$4.89
Total assets
$727.96M
Total liabilities
$542.35M
Debt
$335.63M
Equity
$147.94M
Working capital
$65.21M
Debt to equity
2.27
Current ratio
1.31
Quick ratio
0.8
Net debt/EBITDA
5.94
Margins
Efficiency
Dividend
EBITDA margin
8.6%
Gross margin
67.7%
Net margin
-5.9%
Operating margin
-8.3%
Return on assets
-4.4%
Return on equity
-21.7%
Return on invested capital
0%
Return on capital employed
0%
Return on sales
0%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BVS stock price
How has the Bioventus stock price performed over time
Intraday
1.49%
1 week
4.28%
1 month
-6.21%
1 year
88.69%
YTD
-9.43%
QTD
3.93%
Financial performance
How have Bioventus's revenue and profit performed over time
Revenue
$573.28M
Gross profit
$388.23M
Operating income
-$47.7M
Net income
-$33.54M
Gross margin
67.7%
Net margin
-5.9%
BVS's net margin has soared by 81% YoY and by 17% QoQ
The company's net income has surged by 79% YoY and by 15% QoQ
Bioventus's operating margin has surged by 65% YoY and by 19% QoQ
The operating income has soared by 60% YoY and by 15% from the previous quarter
Growth
What is Bioventus's growth rate over time
Valuation
What is Bioventus stock price valuation
P/E
N/A
P/B
5.22
P/S
1.07
EV/EBIT
N/A
EV/EBITDA
21.68
EV/Sales
1.87
Bioventus's EPS has soared by 79% YoY and by 13% from the previous quarter
BVS's price to book (P/B) is 66% more than its 5-year quarterly average of 3.1 and 17% more than its last 4 quarters average of 4.4
Bioventus's equity has decreased by 15% YoY
The revenue is up by 12% year-on-year and by 3.3% since the previous quarter
BVS's P/S is 5% above its 5-year quarterly average of 1.0 and 5% above its last 4 quarters average of 1.0
Efficiency
How efficient is Bioventus business performance
The return on invested capital has surged by 100% since the previous quarter and by 100% year-on-year
Bioventus's ROS has soared by 100% from the previous quarter and by 100% YoY
The return on assets has surged by 76% year-on-year and by 12% since the previous quarter
The ROE has soared by 75% year-on-year and by 11% since the previous quarter
Dividends
What is BVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BVS.
Financial health
How did Bioventus financials performed over time
Bioventus's total assets is 34% more than its total liabilities
BVS's current ratio is down by 14% year-on-year and by 7% since the previous quarter
The quick ratio has declined by 12% year-on-year but it rose by 2.6% since the previous quarter
BVS's debt is 127% higher than its equity
BVS's debt is down by 15% YoY and by 13% QoQ
Bioventus's equity has decreased by 15% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.